• 
• 
• 
• 
• 
• 

Press releases 2008

• 12/19/2008
  Ad-hoc: Excellent Phase III-results with BF-200 ALA

• 12/18/2008
  Biofrontera and Grünenthal Pharma AG sign Letter of Intent on the production of Reliéva and BF-200 ALA

• 11/21/2008
  Patient recruitment in Biofrontera’s phase II study in severe chronic urticaria completed

• 10/7/2008
  Patient treatment in phase III study with BF-200 ALA for actinic keratosis completed

• 8/26/2008
  Informations about the license agreement between Biofrontera and DSE Healthcare Solutions on the distribution of Reliéva™ in the USA

• 8/26/2008
  Ad-hoc: Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)

• 8/26/2008
  Biofrontera AG reports first half financial results for 2008

• 8/5/2008
  Ad-hoc: Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)

• 7/24/2008
  Statement on corporate and share price development (German only)

• 6/12/2008
  Biofrontera acquires world-wide license on a product family for the treatment of psoriasis and atopic dermatitis

• 4/30/2008
  Biofrontera reports financial results for fiscal year 2007

• 4/2/2008
  Rapid progress in phase III studies for BF-200 ALA in the treatment of actinic keratosis

• 3/6/2008
  Biofrontera expands the patent protection for its compound BF-1 in migraine prophylaxis

• 2/21/2008
  Biofrontera initiates a Phase II study for psoriasis

• 1/28/2008
  Biofrontera expands its team with experienced marketing and sales specialists

• 1/14/2008
  Phase III clinical trial of BF-200 ALA for Actinic Keratosis started